Dr. Vikas Bhambhani, M.D
Medical Genetics (Clinical Genetics (M.D.) Physician)
At a glance
- In the NPI registry since
- 2010
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Genetics (M.D.) Physician primary
MN license 56266
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $80,031 in research payments for these studies, mostly to the institutions running them.
- Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
Genzyme Corporation · Active, not recruiting · NCT04910776 - Pompe Disease Registry Protocol
Sanofi US Services Inc. · Recruiting · NCT00231400 - An Observational Disease and Clinical Outcomes Registry of Patients with Lysosomal Acid Lipase (LAL) Deficiency
Alexion Pharmaceuticals, Inc. - TAK-665-4003: an open-label, multicenter, phase 4 study to assess the effects of a prophylactic immune tolerizing regimen in mps ii treatment-nave patients planned to receive elaprase who are at risk of developing per…
Takeda Pharmaceuticals U.S.A., Inc. - PASS to Assess Long-term Safety in Patients with Pompe disease in the Commercial Setting
Genzyme Corporation - Gaucher disease outcome survey (gos) an observational, international, multicenter, long-term registry of patients with gaucher disease
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.